Deficiency in thrombin-activatable fibrinolysis inhibitor (TAFI) protected mice from ferric chloride-induced vena cava thrombosis

By Wang Xinkang   Smith Patricia   Hsu Mei-Yin   Tamasi Joseph   Bird Eileen   Schumacher William  

Journal of Thrombosis and Thrombolysis, Vol. 23, Iss. 1, 2007-02 ,pp. : 41-49

Springer Publishing Company

Access to resources Recommend Favorite

Thrombin-Activatable Fibrinolysis Inhibitor (TAFI, Plasma Procarboxypeptidase B, Procarboxypeptidase R, Procarboxypeptidase U)

By Bouma B.N.   Marx P.F.   Mosnier L.O.   Meijers J.C.M.  

Thrombosis Research, Vol. 101, Iss. 5, 2001-03 ,pp. : 329-354

Elsevier

Access to resources Recommend Favorite

Activity and Antigen Levels of Thrombin-Activatable Fibrinolysis Inhibitor in Plasma of Patients With Disseminated Intravascular Coagulation

By Watanabe R.   Wada H.   Watanabe Y.   Sakakura M.   Nakasaki T.   Mori Y.   Nishikawa M.   Gabazza E.C.   Nobori T.   Shiku H.  

Thrombosis Research, Vol. 104, Iss. 1, 2001-10 ,pp. : 1-6

Elsevier

Access to resources Recommend Favorite

Changes in Activated Thrombin-Activatable Fibrinolysis Inhibitor Levels Following Thrombolytic Therapy in Ischemic Stroke Patients Correlate with Clinical Outcome

By  

Cerebrovascular Diseases, Vol. 42, Iss. 5-6, 2016-07 ,pp. : 404-414

Karger

Access to resources Recommend Favorite

Thrombin-Activatable Fibrinolysis Inhibitor in Breast Cancer Patients

By  

Medical Principles and Practice, Vol. 20, Iss. 4, 2011-05 ,pp. : 332-335

Karger

Access to resources Recommend Favorite